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Regioselective methods were investigated to prepare N- and O-alkylated isoquinolin-1-ones efficiently. The predicted
regioselective alkylation of the nitrogen with (hetero)benzyl halides was complemented using (hetero)benzylic
Mitsunobu electrophiles to alkylate predominantly at the oxygen. A series of drug-delivery conjugates was prepared
demonstrating control over the site of alkylation. The Mitsunobu reaction provides a new approach to 1-alkoxy-
isoquinolines that were unavailable via previous harsher synthetic methods.
Introduction
Repair and maintenance of chromosomes are, in part, con-
trolled by the addition and removal of polymers of ADP-ribose
to the DNA-binding proteins involved.1 ADP-ribose units are
added by poly(ADP-ribose)polymerase (PARP) and removed
by poly(ADP-ribose)glycohydrolase (PARG). The involvement
of poly(ADP-ribosyl)ation in a wide range of physiological and
pathophysiological processes renders it a useful target to study
biological systems and for therapeutic intervention strategies.
Pathophysiological effects are mediated through overactivity of
the isoform PARP-1, which depletes stores of nicotinamide
adenine dinucleotide (NAD), the PARP substrate, leading to
cell death.
5-Substituted isoquinoline-1-ones are potent inhibitors 2,3
of PARP with potential therapeutic applications in several
diseases, including cancer,4 myocardial infarction,5 diabetes,6
stroke,7 rheumatoid arthritis,8 haemorrhagic shock 3 and retro-
viral infections.9 As a regulatory enzyme, PARP has beneficial
roles in health and detrimental roles in disease and, therefore,
inhibitors need to be targeted selectively to diseased tissues. We
are developing analogues with greater aqueous solubility and
prodrugs for their site-specific release. Our aim is to develop
strategies to control attachment of masking prodrug units via
either the 2-nitrogen or the exocyclic oxygen to compare the
pharmacokinetic and drug release properties of these series of
prodrugs.
Results and discussion
Deprotonation of isoquinolin-1-ones with base and reaction
of the resulting anions with alkyl halides or tosylates are
reported 10–12 to result in alkylation exclusively at nitrogen,
giving 2-alkylisoquinolin-1-ones, although Kaneko et al.13 note
that traces (<2%) of the corresponding O-alkylated products
(1-alkoxyisoquinolines) are also obtained in reactions with 4-
bromobut-1-ene and its homologues. Interestingly, harder
electrophiles, such as triflic anhydride 14 and silylating agents,15
react at exocyclic oxygen, although the nucleophile may be the
neutral molecule in these cases. 1-Alkoxyisoquinolines have
generally been prepared by displacement of halides or other
leaving groups from the 1-position of isoquinolines with nucleo-
philic alkoxides,14,16 although the range of groups that can be
introduced is limited to simple examples by the harsh con-
ditions necessary.
Several routes were employed for the synthesis of the starting
isoquinoline-1-ones used in this study (Scheme 1). Isoquinolin-
1-one 1a (“isocarbostyril”) is commercially available. Our pre-
viously reported synthesis 11 of 5-iodoisoquinolin-1-one 1b, by
Curtius rearrangement of 2-iodocinnamoyl azide and cyclis-
ation of the intermediate 2-(2-iodophenyl)ethenyl isocyanate at
Scheme 1 Synthetic approaches to 5-iodoisoquinolin-1(2H )-one 1b
and 5-(Boc-amino)isoquinolin-1(2H )-one 1d. Reagents and conditions:
i, NaNO2–aq. HCl–KI, 0 C; ii, NH3–MeOCH2CH2OH, reflux; iii,
Boc2O (1.5 equiv.)–Et3N–CH2Cl2–DMF; iv, Boc2O (3.0 equiv.)–Et3N–
CH2Cl2–DMF; v, Boc2O (3.0 equiv.)–Et3N–DMF.
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280 C, proved not to be amenable to the routine preparation of
large quantities and a new route was required. Following the
newer route to 1b, 5-aminoisocoumarin 2 was diazotised and
the diazonium group was replaced with iodine using potassium
iodide; 5-iodoisocoumarin 4 was obtained in good yield
(Scheme 1). Conversion to the isoquinolin-1-one 1b was
achieved in the usual manner, in a reliable 48% yield from 2. 5-
Bromoisoquinolin-1-one 1c was prepared by diazotisation and
Sandmeyer reaction of 5-aminoisocoumarin 2, followed by
replacement of the ring oxygen with nitrogen by treatment with
ammonia at high temperature, as described previously.17
5-Aminoisoquinolin-1(2H )-one 1e is a particularly effective
inhibitor of PARP in vivo 3 but, to be able to study the nucleo-
philic reactivity of the 2-nitrogen and the exocyclic oxygen,
the potentially more nucleophilic 5-amine required protection.
In the first route to 1e, the Boc-amino unit was assembled on
the isocoumarin prior to conversion to the isoquinolinone
(Scheme 1). Reaction of 5-aminoisocoumarin 2 with a small
excess of di-tert-butyl dicarbonate led to the mono-Boc com-
pound 3a, whereas treatment with three equivalents gave the
N,N-diBoc analogue 3b in good yield. As expected, 3a was
converted to the mono-Boc isoquinolinone 1d with ammonia
in refluxing 2-methoxyethanol. When 3b was subjected to the
same conditions, not only was the isocoumarin converted to
the isoquinolinone but also one of the Boc groups was
ammonolysed from the 5-amino function, also giving the
mono-Boc isoquinolinone 1d efficiently. Direct introduction of
Boc protection to 5-aminoisoquinolin-1(2H )-one 1e also gave
1d but in lower yield.
In model studies, (Scheme 2), the reactions of the isoquinolin-
1(2H )-ones 1 with simple benzyl electrophiles were investi-
gated. The 5-unsubstituted isoquinolinone 1a was deproto-
nated with sodium hydride and the anion reacted with benzyl
bromide to give the N-benzylated compound 6a as the only
isolable product.11 Generation of the anions from the 5-halo-
isoquinolinones 1b,c with the soluble non-nucleophilic base
lithium bis(trimethylsilyl)amide was technically more facile.
Again, alkylation with the benzyl chlorides 5b,c gave only the
products of N-alkylation, 6b,c, respectively.11 In contrast,
reaction of 1a with benzyl alcohol under Mitsunobu conditions
gave only the O-benzylated product 7.
Extension of the study to pseudobenzylic 5-membered ring
heterocycles produced a similar outcome. The anion derived
from isoquinolinone 1a reacted only at nitrogen 11 with 2-
chloromethylfuran 8a and 5-nitrofuran-2-yl tosylates 8b,
affording the isoquinolinones 9a,b. The yield of the nitro-
furanylmethylisoquinolinone was low, probably owing to side-
reactions involving the relatively acidic methylene protons
in 8b. Similarly, the anion of 1a reacted with 2-chloro-
methylthiophene 8c only at nitrogen, giving 9c. However, this
anion only served to degrade the corresponding nitrothiophene
electrophile 2-chloromethyl-5-nitrothiophene;18 the methylene
protons are presumably even more acidic in these molecules
than are those in 8b. In this series, the Mitsunobu alkylations
were carried out using (5-nitro-2-thienyl)methanol 8d as the
electrophile; this represents a sterner test of the applicability of
the process, owing to the possibility of reduction of the nitro
group by the triphenylphosphine. Reaction of the isoquino-
linones 1a–c with 8d under the standard Mitsunobu conditions,
however, led to the O-alkylated products 10a–c, respectively,
in moderate yields but without any trace of formation of N-
alkylated materials.
Thus, in the cases of the monocyclic benzylic electrophiles 5
and 8, the outcomes of the reactions are clearly defined: con-
ventional alkylation with benzylic halides and tosylates gives
only reaction at nitrogen, whereas the Mitsunobu conditions
give exclusively the O-alkylated products. With the bicyclic
electrophiles 11 based on the 4,7-dioxoindole-3-methylene unit,
however, the outcomes are more subtle. All attempts to alkylate
the anions derived from the isoquinolinones 1a–c with the
chloromethyl-1H-indole-4,7-dione 11a 19 failed. The indole-
dione unit was destroyed under the basic reaction conditions;
the isoquinolinone anions are clearly much more basic than are
the phenolate anions which are reported 19 to react smoothly
with this reagent. Naylor et al.19 observed solvent-dependent
regioselectivity in alkylation of 2-fluorophenolate and 4-fluoro-
phenolate, ethyl acetate favouring C-alkylation and DMF
favouring O-alkylation. When the isoquinolinones 1a–d were
treated with the corresponding alcohol 11b under Mitsunobu
conditions, both the N-alkylated isoquinolinones 12 and the
1-alkoxyisoquinolines 13 were obtained, although never as
mixtures. In repeated experiments, the 5-unsubstituted iso-
quinolinone 1a only reacted at oxygen, giving 13a. In contrast,
the 5-bromo- and 5-Boc-amino analogues 1c,d gave only the
N-linked compounds 12c,d. Most surprisingly, the 5-iodoiso-
quinolin-1(2H )-one 1b gave the N-linked product 12b and the
O-linked product 13b not as a mixture but as the sole isolable
products from different experiments under apparently the same
conditions.
Distinction between the structures of the N-alkyliso-
quinolinones 6, 9, 12 and 1-alkoxyisoquinolines 7, 10, 13 was
made primarily on the basis of their 1H and 13C NMR spectra
(Table 1). Taking the isomeric pair 6a and 7, the NCH2 protons
of 6a resonate at δ 5.20, whereas the OCH2 proton signal of 7
appears downfield at δ 5.58, due to the greater electronegativity
of oxygen. Significant changes in chemical shift are also seen
for two of the isoquinoline protons. In 6a, the 3-H resonates at
δ 7.06 and the 4-H at δ 6.46; in 7, the corresponding signals
are at δ 8.00 and δ 7.25, respectively, reflecting the enamide
character of the isoquinolin-1(2H )-one and the greater
aromaticity of the 1-alkoxyisoquinoline. The signals of the
protons of the carbocyclic rings are relatively similar for the
two compounds and are not diagnostic. Using this guide,
6b,c can be identified as N-benzylisoquinolinones in showing
chemical shifts for the CH2 protons and for 3-H and 4-H as
does 6a. Further confirmation of the structure of 6b was given
by an unequivocal synthesis, as shown in Scheme 3. 5-Bromo-
isocoumarin 14 (prepared as described previously by us 17) was
condensed with 4-methoxybenzylamine to give 6b in modest
yield. Since the methoxybenzyl unit was attached to nitrogen in
the reagent, the product of this reaction must be 5-bromo-N-(4-
methoxybenzyl)isoquinolin-1(2H )-one 6b, rather than any O-
linked isomer. The general pattern of proton chemical shifts
was similar for the furans 9a,b and the thiophenes 9c, 10a–c.
In the N-linked compounds 9, the CH2 protons resonated in
the range δ 5.1–5.4 and in the O-linked 10, the corresponding
signals appeared at δ ca. 5.7. In 9, the isoquinoline 3-H and 4-H
signals were at δ 7.1–7.5 and δ 6.4–6.6, whereas in 10, the signals
Table 1 Selected NMR chemical shifts a for the N-alkyliso-
quinolinones and 1-alkoxyisoquinolines
Compound δH (CH2) δC (CH2) δH (3-H) δH (4-H)
6a 5.20 b 51.6 b 7.06 b 6.46 b
6b 5.22 b 51.9 b 7.19 b 6.72 b
6c 5.15 c 7.18 6.82
7 5.58 c 8.00 7.25
9a 5.17 b 44.2 b 7.14 b 6.45 b
9b 5.23 b c 7.24 b 6.58 b
9c 5.34 c 7.5 6.49
10a 5.74 62.3 8.00 7.30
10b 5.74 62.8 8.10 7.49
10c 5.75 62.9 8.12 7.65
12b 5.29 32.6 7.80 6.66
12c 5.30 32.6 7.82 6.77
12d 5.25 c 7.47 6.57
13a 5.72 53.4 8.00 7.20
13b 5.71 56.4 8.08 7.40
a Spectra recorded of solutions in CDCl3. 
b Data taken from ref. 10. c Not
determined. 
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Scheme 2 Studies on the N- and O-alkylation of isoquinolin-1(2H )-ones 1a–d. Reagents: i, NaH–DMF–5a; ii, LiN(SiMe3)2–THF–5b–NaI;
iii, LiN(SiMe3)2–THF–5c–NaI; iv, Ph3P–diethyl azodicarboxylate (DEAD)–5d–THF; v, LiN(SiMe3)2–THF–8a–NaI; vi, NaH–DMF–8b;
vii, LiN(SiMe3)2–THF–8c; viii, Ph3P–DEAD–8d–THF; ix, Ph3P–DEAD–11b–THF.
Scheme 3 Unequivocal synthesis of 5-bromo-2-(4-methoxybenzyl)iso-
quinolin-1(2H )-one 6c. Reagents and conditions: i, 4-MeOBnNH2,
MeOCH2CH2OH, reflux.
were at δ 8.0–8.1 and δ 7.3–7.7, respectively. Clearly, the range
of chemical shifts for 4-H in 10 is greater than that for 3-H, as
the former is expected to be more influenced by the nature
of the 5-substituent than is the latter. Similarly, in the indole-
4,7-dione series 12 and 13, highly diagnostic trends in chemical
shift were observed. In these series, the nature of the O- or
N-substituent is constant, so the chemical shifts should be
more directly comparable. Hence, the resonances for the CH2
protons of 12b–d fall in the very narrow range δ 5.25–5.30 and
the corresponding signals for 13a,b are at δ 5.72 and δ 5.71,
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respectively. As expected, the chemical shifts of 3-H and 4-H
are sensitive to the nature of the 5-substituent. The chemical
shifts in the 13C NMR spectra show analogous trends, although
the ranges are wider and sometimes overlapping. In the N-
linked isoquinolinones 6, 9, 12, the 13CH2 peaks are in the range
δ 32–52; whereas, in the O-linked isoquinolines 10, 13, the
corresponding range is δ 53–63.
In this paper, we have reaffirmed the regioselectivity of
alkylation of isoquinolin-1-one anions with (hetero)benzyl
halides as taking place essentially exclusively at nitrogen. In
contrast, reaction with benzylic and heterobenzylic Mitsunobu
electrophiles takes place at oxygen in most cases. In some
cases, the outcome of the reaction is extremely sensitive to the
reaction conditions and to the nature of the 5-substituent of the
isoquinolin-1-one; mixtures of products were never observed.
Although Mitsunobu reactions with isoquinolin-1-ones as the
nucleophilic component are previously unreported, Manhas
et al.20 achieved reaction of quinazolin-4-ones with steroid
alcohols through the exocyclic oxygen of the heterocycles.
These observations are consistent with regioselectivity being
controlled by the hardness/softness of the nucleophiles and
electrophiles involved. Such control is also evident in the O-
selective alkylation of amides and the S-selective alkylation
of thioamides with alcohols under Mitsunobu conditions;21
phthalimide, of course, is alkylated at nitrogen in a synthetically
useful approach to primary amines.22 The Mitsunobu electro-
phile derived from the 4,7-dioxoindol-3-ylmethanol 11b must
be very close to matching hardness with the O and N nucleo-
philic centres of the isoquinolinone anions.
The Mitsunobu reaction is shown here to offer a potential
approach to 1-alkoxyisoquinolines carrying useful functionality
in the 1-substituent; such compounds are not available through
previous harsh synthetic methods. The 2-(4,7-dioxo-1H-indol-
3-ylmethyl)isoquinolin-1(2H )-ones and 1-[(4,7-dioxo-1H-
indol-3-yl)methoxy]isoquinolines may represent a new class of
prodrugs to target PARP inhibitors to hypoxic regions of solid
tumours 17 and other diseased tissues.
Experimental
NMR spectra were recorded on samples in CDCl3, unless
otherwise stated. Mass spectra were obtained by fast atom
bombardment (FAB) in the positive ion mode, unless otherwise
stated. The stationary phase for chromatography was silica gel.
Melting points are uncorrected. Solutions in organic solvents
were dried with MgSO4. Solvents were evaporated under
reduced pressure. Experiments were conducted at ambient
temperature, unless otherwise stated. The brine was saturated.
DEAD refers to diethyl azodicarboxylate. DMF refers to
dimethylformamide.
5-Iodoisoquinolin-1(2H )-one 1b
Compound 4 (300 mg, 1.1 mmol), in 2-methoxyethanol (50
cm3), was saturated with ammonia for 1 h after which the
mixture was boiled under reflux for 24 h. Evaporation
yielded the isoquinolinone 1b as pale buff crystals (200 mg,
68%): mp 239–242 C (lit.11 mp 238–244 C); δH 6.67 (1 H, d,
J = 7.4 Hz, 4-H), 7.13 (1 H, d, J = 7.4 Hz, 3-H), 7.17 (1 H,
t, J = 7.5 Hz, 7-H), 8.15 (1 H, dd, J = 7.5, 1.1 Hz, 6-H), 8.35
(1 H, dd, J = 7.5, 1.1 Hz, 8-H) and 11.20 (1 H, s, NH).
5-(1,1-Dimethylethoxycarbonylamino)isoquinolin-1(2H )-one 1d
Method A. Compound 3a was treated with ammonia, as in
Method B, to give 1d (76%) with properties as below.
Method B. Compound 3b (68 mg, 0.19 mmol), in 2-methoxy-
ethanol (10 cm3), was saturated with NH3 for 1 h after which
the mixture was boiled under reflux for 24 h. Evaporation and
chromatography (ethyl acetate–hexane 1 : 1) gave 1d (35 mg,
71%) as pale yellow crystals: mp >230 C (Found: C, 63.5; H,
6.28; N, 10.58. C14H16N2O30.25 H2O requires C, 63.60; H, 6.22,
N, 10.20%); νmax (KBr)/cm
1 3320, 1690 and 1670; δH (CDCl3)
1.54 (9 H, s, But), 6.58 (1 H, d, J 7.3, 4-H), 6.61 (1 H, brs,
NHBoc), 7.22 (1 H, d, J 7.3, 3-H), 7.49 (1 H, t, J = 8.1 Hz, 7-H),
8.04 (1 H, d, J = 8.1 Hz, 6-H), 8.22 (1 H, d, J = 8.1 Hz, 8-H) and
10.60 (1 H, brs, NH); m/z 261.1235 (M  H) (C14H17N2O3
requires 261.1239) and 260.1169 (M) (C14H16N2O3 requires
260.1161).
Method C. Triethylamine (1.8 g, 18 mmol) was added to 5-
aminoisoquinolin-1(2H )-one 1e 3 (600 mg, 3.7 mmol) in DMF
(40 cm3) and the solution was cooled to 0 C. Di-tert-butyl
dicarbonate (2.45 g, 11.2 mmol) was added in portions during
2 d. The evaporation residue, in ethyl acetate, was washed
with water and brine and was dried. Evaporation and chroma-
tography (ethyl acetate–hexane 1 : 4) gave 1d (0.57 g, 60%) as a
pale yellow powder with properties as above.
5-(1,1-Dimethylethoxycarbonylamino)isocoumarin 3a
To 5-aminoisocoumarin 17 2 (700 mg, 4.4 mmol) in dichloro-
methane (3.0 cm3) was added DMF (3.5 cm3) and triethylamine
(0.070 cm3). The solution was cooled to 0 C, di-tert-butyl
dicarbonate (1.4 g, 6.4 mmol) in CH2Cl2 (3.0 cm
3) was added
and the mixture was stirred for 4 d. The evaporation residue,
in ethyl acetate, was washed with water and brine. Evaporation
and chromatography (ethyl acetate–hexane 1 : 4) gave 3a (895
mg, 79%) as very pale yellow crystals: mp 188–190 C (Found:
C, 64.20; H, 5.83; N, 5.35. C14H15N1O4 requires C, 64.36;
H, 5.75; N, 5.36%); νmax (KBr)/cm
1 3320, 1720 and 1682;
δH 1.45 (9 H, s, Bu
t), 6.49 (1 H, d, J = 5.9 Hz, 4-H), 6.50 (1 H,
br s, NH), 7.22 (1 H, d, J = 5.9 Hz, 3-H), 7.42 (1 H, t, J = 7.9 Hz,
7-H), 7.97 (1 H, d, J = 7.9 Hz, 6-H) and 8.02 (1 H, d, J = 7.9 Hz,
8-H); m/z 262.1085 (M  H) (C14H16N1O4 requires 262.1079),
261.1008 (M) (C14H15N1O4 requires 261.1001) and 206 (M 
But).
5-[N,N-Bis(1,1-dimethylethoxycarbonyl)amino]isocoumarin 3b
To 5-aminoisocoumarin 17 2 (100 mg, 0.62 mmol) in dichloro-
methane (1.0 cm3) was added DMF (0.5 cm3) and triethylamine
(0.010 cm3). The solution was cooled to 0 C and di-tert-butyl
dicarbonate (403 mg, 1.84 mmol) in dichloromethane (1.0 cm3)
was added during 10 min. The mixture was stirred for 4 d. The
evaporation residue, in ethyl acetate, was washed with water
and brine. Evaporation and chromatography (ethyl acetate–
hexane 1 : 4) gave 3b (130 mg, 58%) as white crystals: mp 165–
167 C; νmax (KBr)/cm
1 1720; δH 1.38 (18 H, s, 2 × Bu
t), 6.47
(1 H, dd, J = 5.9, 0.6 Hz, 4-H), 7.32 (1 H, d, J = 5.9 Hz, 3-H),
7.53 (1 H, t, J = 7.9 Hz, 7-H), 7.54 (1 H, dd, J = 7.9, 1.3 Hz,
6-H) and 8.29 (1 H, ddd, J = 7.9, 1.3, 0.6 Hz, 8-H); m/z 362.1617
(M  H) (C19H24N1O6 requires 362.1604), 361.1544 (M)
(C19H23N1O6 requires 361.1525), 262 (M  H  Boc) and 206
(M  H  Boc  But).
5-Iodoisocoumarin 4
Sodium nitrite (2.6 g, 37.3 mmol) in water (200 cm3) was added
to 5-aminoisocoumarin 2 17 (7.0 g, 43.4 mmol) in aq. hydro-
chloric acid (4.5 M, 250 cm3) at 0 C. A chilled solution of
potassium iodide (10.0 g, 60 mmol) in water (250 cm3) was
added during 10 min. The mixture was stirred for 2 h before
extraction with ethyl acetate. Evaporation and chromatography
(hexane–ethyl acetate 4 : 1) yielded 4 (8.3 g, 70%) as off-white
crystals: mp 155–156 C; δH ((CD3)2SO) 6.75 (1 H, d, J = 5.9 Hz,
3-H), 7.37 (1 H, d, J = 7.9 Hz, 7-H), 7.75 (1 H, d,J = 5.9 Hz,
4-H), 8.22 (1 H, d, J = 7.6 Hz, 6-H) and 8.31 (1 H, d, J = 7.9 Hz,
8-H). This material was used without further purification or
characterisation.
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5-Bromo-2-(4-methoxyphenylmethyl)isoquinoline-1(2H )-one 6c
5-Bromoisocoumarin 14 17 (100 mg, 0.44 mmol) in 2-methoxy-
ethanol (1.0 cm3) was boiled under reflux with 4-methoxy-
benzylamine (61 mg, 0.44 mmol) for 24 h. Evaporation,
chromatography (hexane–ethyl acetate 5 : 1) and trituration
(diethyl ether) gave 6c (40 mg, 27%) as white crystals: mp 97–
100 C (lit.11 mp 98–100 C); νmax (KBr)/cm
1 1640, 1610 and
690; δH 3.79 (3 H, s, Me), 5.15 (2 H, s, CH2), 6.82 (1 H, dd,
J = 7.6, 0.5 Hz, 4-H), 6.87 (2 H, d, J = 8.5 Hz, Ph 3,5-H2), 7.18
(1 H, d, J = 7.6 Hz, 3-H), 7.27 (2 H, J = 8.5 Hz, Ph 2,6-H2), 7.33
(1 H, t, J = 8.0 Hz, 7-H), 7.87 (1 H, dd, J = 8.0, 1.5 Hz, 6-H) and
8.43 (1 H, ddd, J = 8.0, 1.5, 0.5 Hz, 8-H).
1-Phenylmethoxyisoquinoline 7
Isoquinolin-1(2H )-one 1a was treated with triphenylphosphine,
DEAD and 5d, as for the synthesis of 10a, except that the
chromatographic eluant was ethyl acetate, to give 7 (39%) as a
colourless oil: δH 5.58 (2 H, s, CH2), 7.25 (1 H, d, J = 6.2 Hz,
4-H), 7.36 (5 H, m, Ph-H5), 7.55 (1 H, dd, J = 8.5, 8.2 Hz, 7-H),
7.66 (1 H, t, J = 8.2 Hz, 6-H), 7.70 (1 H, d, J = 8.2 Hz, 5-H), 8.00
(1 H, d, J = 6.2 Hz, 3-H) and 8.31 (1 H, d, J = 8.5 Hz, 8-H);
MS (EI) m/z 235.0997 (M) (C16H13ON requires 235.0989).
2-(2-Thienylmethyl)isoquinolin-1(2H )-one 9c
2-Chloromethylthiophene 23 8c (270 mg, 2.0 mmol) and sodium
iodide (5 mg) were added to isoquinolin-1-one 1a (200 mg,
1.4 mmol) and lithium bis(trimethylsilyl)amide (1.0 M in THF,
2.8 mL, 2.8 mmol) in dry DMF (10 cm3) and the mixture was
stirred for 2 d under Ar. The evaporation residue, in ethyl
acetate, was washed with water (2×) and brine (2×) and was
dried. Evaporation and chromatography (ethyl acetate–hexane
1 : 1) gave 9c (150 mg, 45%) as a pale buff glass; νmax (KBr)/cm
1
1640; δH 5.34 (2 H, s, CH2), 6.49 (1 H, d, J = 7.3 Hz, iso-
quinoline 4-H), 6.95 (1 H, dd, J = 5.1, 3.5 Hz, thiophene 4-H),
7.11 (1 H, br d, J = 3.5 Hz, thiophene 3-H), 7.14 (1 H, d, J = 7.3
Hz, isoquinoline 5-H), 7.24 (1 H, dd, J = 5.3, 1.4 Hz, thiophene
5-H), 7.5 (2 H, m, isoquinoline 3,7-H2), 7.62 (1 H, t, J = 7.5 Hz,
isoquinoline 6-H) and 8.45 (1 H, d, J = 7.5 Hz, isoquinoline
8-H); δC 46.5, 106.6, 125.9, 126.1, 126.8, 126.9, 127.3, 128.0
(2 × C), 130.6, 132.3, 136.9, 138.8 and 161.9; m/z 242.0635
(M  H) (C14H11NOS requires 242.0639).
1-(5-Nitro-2-thienylmethoxy)isoquinoline 10a
Isoquinolin-1(2H )-one 1a (90 mg, 0.62 mmol) was stirred with
triphenylphosphine (330 mg, 1.3 mmol) in dry tetrahydrofuran
(20 cm3) under Ar for 5 min. DEAD (209 mg, 1.2 mmol) was
added dropwise. After 15 min, (5-nitro-2-thienyl)methanol 18 8d
(100 mg, 0.63 mmol) was added and the mixture was stirred for
16 h. Evaporation and chromatography (ethyl acetate–hexane
1 : 1) gave 10a (67 mg, 38%) as a pale buff oil: νmax (film)/cm
1
1631; δH 5.74 (2 H, s, CH2), 7.12 (1 H, d, J = 4.0 Hz, thiophene
3-H), 7.30 (1 H, d, J = 6.0 Hz, isoquinoline 4-H), 7.55 (1 H, dd,
J = 8.2, 7.7 Hz, isoquinoline 7-H), 7.70 (1 H, t, J = 7.7 Hz,
isoquinoline 6-H), 7.75 (1 H, d, J = 7.7 Hz, isoquinoline 5-H),
7.80 (1 H, d, J = 4.0 Hz, thiophene 4-H), 8.00 (1 H, d, J = 6.0
Hz, isoquinoline 3-H) and 8.25 (1 H, d, J = 8.2 Hz, isoquinoline
8-H); δC 62.3, 116.1, 126.1, 127.4, 128.1, 128.5, 130.0, 131.5,
131.8, 132.3, 148.2, 158.9 and 165.6; m/z 287.0486 (M  H)
(C14H10N2O3S requires 287.0490).
5-Iodo-1-(5-nitro-2-thienylmethoxy)isoquinoline 10b
5-Iodoisoquinolin-1(2H )-one 1b was treated with triphenyl-
phosphine, DEAD and 8d, as for the synthesis of 10a, to give
10b (30%) as a yellow powder: mp 78–82 C (Found: C, 40.7;
H, 2.09; N, 6.4. C14H9IN2O3S requires C, 40.87; H, 2.18; N,
6.80%); νmax (KBr)/cm
1 1618; δH 5.74 (2 H, s, CH2), 7.12 (1 H,
d, J = 3.9 Hz, thiophene 3-H), 7.27 (1 H, dd, J = 7.4, 8.5 Hz,
isoquinoline 7-H), 7.49 (1 H, d, J = 6.3 Hz, isoquinoline 4-H),
7.83 (1 H, d, J = 3.9 Hz, thiophene 4-H), 8.10 (1 H, d, J = 6.3
Hz, isoquinoline 3-H), 8.22 (1 H, d, J = 7.4 Hz, isoquinoline
6-H) and 8.27 (1 H, d, J = 8.5 Hz, isoquinoline 8-H); δC 62.8,
96.9, 119.7, 120.0, 124.3, 125.9, 127.9, 139.6, 140.5, 141.7, 147.6
and 158.9; MS (EI) m/z 412 (M).
5-Bromo-1-(5-nitro-2-thienylmethoxy)isoquinoline 10c
5-Bromoisoquinolin-1(2H )-one 2 1c was treated with triphenyl-
phosphine, DEAD and 8d, as for the synthesis of 10a, to give
10c (41%) as a yellow powder: mp 128–130 C; νmax (KBr)/cm
1
1616; δH 5.75 (2 H, s, CH2), 7.13 (1 H, d, J = 4.2 Hz, thiophene
3-H), 7.42 (1 H, dd, J = 8.2, 7.8 Hz, isoquinoline 7-H), 7.65
(1 H, d, J = 6.0 Hz, isoquinoline 4-H), 7.84 (1 H, d, J = 4.2 Hz,
thiophene 4-H), 7.97 (1 H, d, J = 7.8 Hz, isoquinoline 6-H), 8.12
(1 H, d, J = 6.0 Hz, isoquinoline 3-H) and 8.25 (1 H, d, J = 8.2
Hz, isoquinoline 8-H); δC 62.9, 115.2, 120.1, 121.5, 123.7, 126.1,
127.5, 128.2, 134.7, 139.0, 140.6, 147.8 and 158.9; m/z 366.9575
(M  H) (C14H9
81BrN2O3S requires 366.9589).
1,2-Dimethyl-3-(5-iodo-1-oxo-2H-isoquinolin-2-ylmethyl)-5-
methoxy-1H-indole-4,7-dione 12b
5-Iodoisoquinolin-1(2H )-one 1b was treated with triphenyl-
phosphine, DEAD and 11b, as for the synthesis of 10a, to give
12b (36%) as a purple powder: mp >230 C; νmax (KBr)/cm
1
1702; δH 2.47 (3 H, s, indole 2-Me), 3.81 (3 H, s, NMe), 3.88
(3 H, s, OMe), 5.29 (2 H, s, CH2), 5.62 (1 H, s, indole 6-H), 6.66
(1 H, d, J = 7.9 Hz, isoquinoline 4-H), 7.12 (1 H, t, J = 7.8 Hz,
isoquinoline 7-H), 7.80 (1 H, d, J = 7.9 Hz, isoquinoline 3-H),
8.11 (1 H, dd, J = 7.8, 1.1 Hz, isoquinoline 6-H) and 8.38 (1 H,
brd, J = 8.2 Hz, isoquinoline 8-H); δC 10.2, 32.6, 42.2, 56.5,
106.5, 109.1, 121.1, 126.7, 127.2, 128.0, 128.7, 134.1, 138.7,
138.9, 142.5, 159.0, 161.1 and 178.1; m/z 489.0309 (M  H)
(C21H18IN2O4 requires 489.0311).
3-(5-Bromo-1-oxo-2H-isoquinolin-2-ylmethyl)-1,2-dimethyl-5-
methoxy-1H-indole-4,7-dione 12c
5-Bromoisoquinolin-1(2H )-one 1c was treated with triphenyl-
phosphine, DEAD and 11b, as for the synthesis of 10a, to give
12c (36%) as a purple powder: mp 278–280 C; νmax (KBr)/cm
1
1695; δH 2.47 (3 H, s, indole 2-Me), 3.81 (3 H, s, NMe),
3.88 (3 H, s, OMe), 5.30 (2 H, s, CH2), 5.62 (1 H, s, indole 6-H),
6.77 (1 H, d, J = 8.0 Hz, isoquinoline 4-H), 7.27 (1 H, dd,
J = 7.8, 7.3 Hz, isoquinoline 7-H), 7.82 (1 H, d, J = 8.0 Hz,
isoquinoline 3-H), 7.84 (1 H, dd, J = 7.3, 0.9 Hz, isoquinoline
6-H) and 8.36 (1 H, br d, J = 7.8 Hz, isoquinoline 8-H); δC 10.2,
32.6, 42.2, 56.5, 104.3, 106.6, 116.1, 120.4, 121.2, 126.8, 127.4,
128.1, 128.5, 128.8, 134.1, 135.6, 136.3, 138.8, 159.3, 161.2
and 178.2; m/z 441.0443 (M  H) (C21H18N2O4Br requires
441.0449).
1,2-Dimethyl-3-[5-(1,1-dimethylethoxycarbonylamino)-1-oxo-
2H-isoquinolin-2-ylmethyl]-5-methoxy-1H-indole-4,7-dione 12d
Compound 1d was treated with triphenylphosphine, DEAD
and 11b, as for the synthesis of 10a, to give 12d (12%) as an
orange solid: mp >230 C; δH 1.54 (9 H, s, Bu
t), 2.47 (3 H, s,
indole 2-Me), 3.81 (3 H, s, NMe), 3.88 (3 H, s, OMe), 5.25 (2 H,
s, CH2), 5.62 (1 H, s, indole 6-H), 6.57 (1 H, d, J = 8.0 Hz,
isoquinoline 4-H), 7.27 (1 H, t, J = 8.0 Hz, isoquinoline 7-H),
7.47 (2 H, m, isoquinoline 3,6-H2) and 8.21 (1 H, d, J = 7.8 Hz,
isoquinoline 8-H).
1,2-Dimethyl-3-(isoquinolin-1-yloxymethyl)-1H-indole-4,7-dione
13a
Isoquinolin-1(2H )-one 1a was treated with triphenylphosphine,
DEAD and 11b, as for the synthesis of 10a, to give 13a (40%) as
a red powder: mp >230 C; νmax (KBr)/cm
1 1725, 1694; δH 2.38
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(3 H, s, indole 2-Me), 3.80 (3 H, s, NMe), 3.89 (3 H, s, OMe),
5.62 (1 H, s, indole 6-H), 5.72 (2 H, s, CH2), 7.20 (1 H, d, J = 5.8
Hz, isoquinoline 4-H), 7.45 (1 H, td, J = 8.2, 1.1 Hz, iso-
quinoline 7-H), 7.61 (1 H, td, J = 8.2, 1.1 Hz, isoquinoline 6-H),
7.70 (1 H, d, J = 8.2 Hz, isoquinoline 5-H), 8.00 (1 H, d,
J = 5.8 Hz, isoquinoline 3-H) and 8.17 (1 H, d, J = 8.6 Hz,
isoquinoline 8-H); δC 9.8, 50.8, 53.4, 56.4, 114.8, 117.3, 119.8,
122.0, 124.4, 125.9, 126.4, 129.0, 130.3, 137.9, 138.0, 139.6,
142.4, 159.7, 160.3, 177.6 and 178.9; MS (EI) m/z 363.1346
(M) (C21H18N2O4 requires 363.1344).
1,2-Dimethyl-3-(5-iodoisoquinolin-1-yloxymethyl)-5-methoxy-
1H-indole-4,7-dione 13b
2-Iodoisoquinolin-1(2H )-one 1c was treated with triphenyl-
phosphine, DEAD and 11b, as for the synthesis of 10a, to give
13b (39%) as a purple powder: mp >230 C; νmax (KBr)/cm
1
1702; δH 2.37 (3 H, s, indole 2-Me), 3.81 (3 H, s, NMe), 3.88
(3 H, s, OMe), 5.62 (1 H, s, indole 6-H), 5.71 (2 H, s, CH2), 7.16
(1 H, dd, J = 8.3, 7.4 Hz, isoquinoline 7-H), 7.40 (1 H, d, J =
6.1 Hz, isoquinoline 4-H), 8.08 (1 H, d, J = 6.1 Hz, isoquinoline
3-H), 8.15 (1 H, dd, J = 7.4, 1.0 Hz, isoquinoline 6-H) and
8.20 (1 H, br d, J = 8.3 Hz, isoquinoline 8-H); δC 9.9, 32.4, 56.4,
58.6, 106.6, 117.0, 118.5, 120.6, 125.1, 127.5, 128.9, 134.5,
138.0, 139.5, 141.1, 159.7, 160.5, 177.6 and 178.9; m/z 489.0309
(M  H) (C21H18IN2O4 requires 489.0311).
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